

1. Allen KE, Clark ER, Jordan VC (1980): *Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships*. Br J Pharmacol. 71:83-9
2. Aloe L, Leon A, Levi-Montalcini R (1993). *A proposed autacoid mechanism controlling mastocyte behaviour*. Agents Actions, 39: C145-C147.
3. Anglana F, Lippa P, Ronca S, Pelisse M (2003): *Trattato di patologia vulvare*, vol 1, cap 3: Fisiologia e omeostasi del Distretto Vulvo-Vestibolo-Vaginale: 49-59.
4. Benassi L, Graziottin A (2006): *Vulvodinia e vestibolite vulvare*. CIC Edizioni Internazionali
5. Bergeron S, Binik YM, Khalife S, Pagidas K (1997). *Vulvar vestibulitis syndrome: a critical review*. Clin. J. Pain, 13(1): 27-42.
6. Boccardo F, Bruzzi A, Rubagatti G (1981): *Estrogen-like action of Tamoxifen on vaginal epithelium in breast cancer patients*. Oncology 38:281-285
7. Broso P, Buffetti G, Sacco A (1994). *La vestibolite vulvare*. Min. Ginecol., 46(3): 109-14
8. Bohm-Starke N, Hilliges M, Falconer C, Rylander E (1998). *Increased intraepithelial innervation in women with vulvar vestibulitis syndrome*. Gynecol. Obstet. Invest., 46: 256-260.
9. Bohm-Starke N, Hilliges M, Falconer C, Rylander E (1999). *Neurochemical characterization of the vestibular nerves in women with vulvar vestibulitis syndrome*. Gynecol. Obstet. Invest., 48: 270-275.
10. Bueb JL, Lambert DM, Tschirhart EJ (2001). *Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro*. Bioch. Bioph. Acta, 1538: 252-259.
11. Capasso I, Esposito E, Migliaccio R, D' Aiuto G (2006): *Uso di Adelmidrol in donne operate di ca. mammario ed in trattamento con ormonoterapia affette da vulvovaginite*. Data on file
12. Chadha S, Gianotten WL, Drogendijk AC, Weijmar Schultz WC, Blindeman LA, van der Meijden WI (1998). *Histopathological features of vulvar vestibulitis*. Int. J. Gynecol. Pathol., 17: 7-11.
13. Ellmen J, Hakulinen P, Partanen A, Hayes DF (2003): *Estrogenic effects of Toremifene and Tamoxifen in postmenopausal breast cancer patients*. Breast Cancer Res Treat. 82:103-11
14. De Pas T, Mandala M, Curigliano G, Peccatori F (2000). *Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703*. Obst. Gynaecol., 95 (6 Pt2): 1030.
15. Donofrio P. (2003): *Valutazione dell'efficacia e della tollerabilità di Saginil gel nel trattamento di donne affette da vulvovaginiti e vulvovestiboliti aspecifiche*. Epitech Group data on file.
16. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995). *Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide*. PNAS USA, 92: 3376-3380.
17. Farrell AM, Millard PR, Schomberg KH, Wojnarowska (1999). *An infective aetiology for vulval lichen sclerosus re-addressed*. Cl. Exp. Dermatol., 24: 479-483.
18. Ferrazzi E, Cartei G, Mattarazzo R, Fiorentino M (1977): *Oestrogen-like effect of Tamoxifen on vaginal epithelium*. Br Med J. 1:1351-2
19. Foster DC, Palmer M, Marks J (1999). *Effect of vulvovaginal estrogen on sensorimotor response of the lower genital tract: a randomised controlled trial*. Obstet. Gynecol., 94: 232-237.
20. Ghannadan M, Baghestanian M, Wimazal F, Eisenmenger M, Latal D, Kargul G, Walchshofer S, Sillaber C, Lechner K, Valent P (1998). *Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies*. J. Invest. Dermatol., 111: 689-695.
21. Giraldo P, Neuer A, Korneeva IL, Ribeiro-Filho A, Simoes JA, Witkin SS (1999). *Vaginal heat shock protein expression in symptom-free women with a history of recurrent vulvovaginitis*. Am. J. Obstet. Gynecol., 180: 524-529.
22. Giraldo P, Von Nowakonski A, Gomes FAM, Linhares I, Neves NA, Witkin S (2000). *Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal Candidiasis*. Obst & Gynecol., 95: 413-416.
23. Graziottin A. (2003) *Etiology and diagnosis of coital pain*. J. Endocrinol Invest., 26:115-21.
24. Handa VL, Stice CW (2000). *Fungal culture findings in cyclic vulvitis*. Obstet. Gynecol., 96: 301-303.
25. Harmanli OH, Cheng GY, Niyirjesy P, Chatwani A, Gaughan JP (2000). *Urinary tract infections in women with bacterial vaginosis*. Obstet. Gynecol., 95: 710-712.
26. Hay PE (1998). *Recurrent bacterial vaginosis*. Dermat. Clinics, 16(4): 769-773.
27. Huang J, Roby KF, pace JL, Russell SW, Hunt JS (1995). *Cellular localization and hormonal regulation of inducible nitric oxide synthase in cycling mouse uterus*. J. Lekoc. Biol., 57: 27-35.
28. Jeremias J, Ledger WJ, Witkin SS (2000). *Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis*. Am. J. Obstet. Gynecol., 182: 283-285.
29. John S, Jacobi J, schlaich MP, Delles C, Schmieder RE (2000). *Effects of oral contraceptives on vascular endothelium in premenopausal women*. Am. J. Obstet. Gynecol., 183: 28-33.
30. Kim MS, Chae HJ, Shin TJ, Kim HM, Kim HR (2001). *Estrogen regulates cytokine release in human mast cells*. Immunopharmac. Immunotoxic., 23(4): 495-504.
31. Kobayashi H, Ishizuka T, Okayama Y (2000). *Human mast cells and basophils as sources of cytokines*. Cl. Exp. Allergy, 30: 1205-1212.
32. Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, Levi-Montalcini R (1994). *Mast cells synthesize, store, and release nerve growth factor*. PNAS USA, 91: 3739-3743.
33. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A (1996). *Nerve growth factor: from neurotrophin to neurokine*. TINS, 19: 514-520.
34. Levi-Montalcini R, Dal Toso R, della Valle F, Skaper SD, Leon A (1995). *Update of the NGF saga*. J. Neurol. Sci., 130: 119-127.
35. Love RR, Kurtycz DF, Dumesic DA, Laube DW, Yang Y (2000): *The effects of Tamoxifen on the vaginal epithelium in postmenopausal women*. J Womens Health Gend Based Med. 9:559-63
36. Lundqvist EN, Hofer PA, Olofsson JI, Sjöberg I (1997). *Is vulvar vestibulitis an inflammatory condition? A comparison of histological findings in affected healthy women*. Acta Derm. Venereol., 77: 319-322.
37. Marin MG, King R, Sfameni S, Dennerstein GJ (2000). *Adverse behavioral and sexual factors in chronic vulvar disease*. Am. J. Obstet. Gynecol., 183: 34-38.
38. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A (1996). *N-(2-hydroxyethyl)hexadecanamide is a rally active in reducing edema formation and inflammation hyperalgesia by down-modulating mast cell activation*. Eur. J. Pharmacol., 300 : 227-236.
39. Miyachi Y, Kurosawa M (1998). *Mast cells in clinical dermatology*. Australas J. Dermatol., 39: 14-18
40. Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, Eschenbach DA (2000). *Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium*. Obst. & Gynecol., 96: 431-439.
41. Moraes PSA, Taketomi EA (2000). *Allergic vulvovaginitis*. Ann. Allergy Asthma Immunol., 85: 253-267.
42. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH (1999): *Effect of Tamoxifen on Sexual Functioning in Patients With Breast Cancer*. J of Clin Oncol. 17:1488-1492
43. Mourits MJ, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH (2001): *Tamoxifen treatment and gynecologic side effects: a review*. Obstet Gynecol, 97:855-866
44. Nunnis D (2000). *Vulval pain syndromes*. Br. J. Obst. Gynaecol., 107: 1185-1193.
45. Ridley CM (1998). *Vulvodinia. Theory and management*. Dermatol. Cl., 16(4): 775-778.
46. Sarna AV, Foxman B, Bayirli B, Haefner H, Sobel JD (1999). *Epidemiology of vulvar vestibulitis syndrome: an exploratory case-control study*. Sex. Transm. Inf., 75: 320-326.
47. Sjöberg I, Lundqvist EN (1997). *Vulvar vestibulitis in the north of Sweden. An epidemiologic case-control study*. J. Reprod. Med., 42(3): 166-168.
48. Shafik A, El-Sibai O, Shafik I, Shafik AA (2005): *Immunohistochemical identification of the pacemaker cajal cells in the normal human vagina*. Arch Gynecol Obstet. 272:13-6
49. Sobel JD, Chaim W (1996). *Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis*. J. Cl. Microb., 34: 2497-2499.
50. Sobel JD, Chaim W, Leaman D (1996). *Recurrent vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women*. Obstet. Gynaecol., 88(4 Pt2): 704-706.
51. Sobel JD (1998). *Vulvovaginitis. When Candida becomes a problem*. Dermatol. Clin., 16: 763-768.
52. Stewart EG, Berger BM (1997). *Parallel pathologies? Vulvar vestibulitis and interstitial cystitis*. J. Reprod. Med., 42(3): 131-134.
53. Vliagofis H, Dimitriadu V, Boucher W, Rozniecki JJ, Correia I, Raam S, Theoharides TC (1992). *Estradiol augments while Tamoxifen inhibits rat mast cells secretion*. Int Arch Allergy Immunol. 98:398-409
54. Zhao XJ, McKerr G, Dong Z, Higgins CA, Carson J, Yang ZQ, Hannigan BM (2000). *Expression of oestrogen and progesterone receptors by mast cells alone, but not lymphocytes, macrophages or other immune cells in human upper airways*. Thorax, 56: 205-211.
55. Wasiela M, Brzezinska-Blaszczyk E (2000) *The influence of anaerobic bacteria and mycoplasma isolated from the genital tract on mast cells activation*. Med Dosw Mikrobiol, 52: 389-396.
56. Westrom LV, Willen R (1998). *Vestibular nerve fiber proliferation in vulvar vestibulitis syndrome*. Obstet. Gynecol., 91: 572-576.
57. Wijma B, Jansson M, Nilsson S, Hallböök, Wijma K (2000). *Vulvar Vestibulitis Syndrome and vaginismus*. J. Repr. Med., 45(3): 219-223.